3-Amino-2-methylbenzoic acid | CAS:52130-17-3

We serve 3-Amino-2-methylbenzoic acid CAS:52130-17-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Amino-2-methylbenzoic acid

Chemical Name:3-Amino-2-methylbenzoic acid
CAS.NO:52130-17-3
Synonyms:3-Amino-2-methylbenzoic acid
3-Amino-2-methylbenz
3-AMINO-2-TOLUIC ACID
2-Methyl-3-aMino acid
2-methyl-3-aminobenzoic acid
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 347.3±30.0 °C at 760 mmHg
Melting Point 178-181 °C(lit.)
Molecular Formula C8H9NO2
Molecular Weight 151.163
Flash Point 163.8±24.6 °C
Vapour Pressure 0.0±0.8 mmHg at 25°C
Index of Refraction 1.618
 
Specification:
Appearance:Off-white to yellowish powder
Assay:≥98.0%
Moisture:≤0.5%
Melting Point:182-186°C
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Lenalidomide(CAS:191732-72-6).



Contact us for information like 3-Amino-2-methylbenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methyl-3-aminobenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methyl-3-aMino acid Use and application,2-methyl-3-aminobenzoic acid technical grade,usp/ep/jp grade.


Related News: Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.2-Chloro-4-Methylbenzotrifluoride manufacturer Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.1-Bromo-2-fluoro-4-(trifluoromethoxy)benzene supplier The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.N,3-diphenylaniline vendor We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.